Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

NCT06784193 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)
Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Breast Cancer
Fulvestrant
Palazestrant

Interventions

DRUG: OP-3136
DRUG: Fulvestrant
DRUG: Palazestrant

Sponsor

Olema Pharmaceuticals, Inc.